Centessa Pharmaceuticals Teases ORX750 Phase II Update, Registrational Study Start at Conference [Yahoo! Finance]
Centessa Pharmaceuticals plc - American Depositary Shares (CNTA)
Company Research
Source: Yahoo! Finance
and aims to start registrational studies for rare hypersomnias (NT2 and idiopathic hypersomnia) this quarter while outlining registrational design and regulatory strategy. November low-dose results showed clinically meaningful effects — 20-minute placebo-adjusted MWT improvement in NT1, 10-minute in NT2, normalization of ESS scores and statistically significant benefits in IH — with a favorable safety/tolerability profile and only mild, transient visual events reported. Centessa is escalating doses and testing once-daily and split-dosing to extend duration of action and patient flexibility, expanded the Phase II open-label extension to four weeks with no loss of effect, and is preparing regulatory engagement, commercial hiring, and follow-on orexin assets (ORX142, ORX489). Interested in Centessa Pharmaceuticals PLC Sponsored ADR? Here are five stocks we like better. Wake Up to This Biotech Stock That Still Has Big Potential Upside Centessa Pharmaceuticals (NASDAQ:CNTA) used
Show less
Read more
Impact Snapshot
Event Time:
CNTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNTA alerts
High impacting Centessa Pharmaceuticals plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CNTA
News
- Centessa Pharmaceuticals CEO Touts ORX750 as Best-in-Class as Registration Studies Nearing Start [Yahoo! Finance]Yahoo! Finance
- Forget Centessa Pharmaceuticals: This Rare-Disease Specialist Has a Superior Portfolio and Pipeline [Yahoo! Finance]Yahoo! Finance
- Centessa Pharmaceuticals (CNTA) was upgraded by Wolfe Research to "strong-buy".MarketBeat
- Centessa Pharmaceuticals (NASDAQ:CNTA) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $40.00 price target on the stock.MarketBeat
- Centessa Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswire
CNTA
Earnings
- 8/12/25 - Miss
CNTA
Sec Filings
- 3/18/26 - Form 4
- 3/17/26 - Form 144
- 3/16/26 - Form 4/A
- CNTA's page on the SEC website